anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The complete agreement between the pathophysiological pattern of ischemic stroke and the hemostatic features of LD heparin 10,5Kd confers specificity to the relevant patent claims. In particular, the specific action of Tissue Factor (TF) and its complex with factor VIIa to trigger cerebral thrombosis respectively determines the basic principle of LD heparin in ischemic stroke. It is the TF/F VIIa-complex that constitutes a suitable substrate for LD heparin that is reasonably resistant to classical antithrombin-mediated effects, but is primarily responsive to Tissue Factor Pathway Inhibitor (TFPI). Its abnormal release in LD heparin, in which LMWH (enoxaparin) is more than three times, constitutes the rationale for new indications for stroke. The TFPI-dependent effect is ensured by a controlled reduction in anti-factor Xa activity inhibiting TF/F VIIa, with a ratio of TFPI and anti-factor Xa activity expressed in the AUC of the two heparins differing by a factor of three. Compared with other similar medicines, the LD heparin not only has the antithrombotic effect which is centered on diseases, but also solves the bleeding risk: due to the "double truncation" of the molecular spectrum, i.e. by reducing its low molecular and very long molecular species, the main source of bleeding can be excluded. The list of accessory properties, in particular adequate pharmacokinetics, reduced peak plasma concentrations, lack of plasma accumulation in age-dependent renal decline and renal insufficiency, availability of effective and sensitive monitoring (APTT), and finally, but not least, the rapid and complete reversibility of anticoagulation compared to LMWH confirm the specificity of the indications. In general, multifunctional improvements in LD heparin aim to increase the benefit-risk ratio ("therapeutic window"), with specific shapes adopted in cerebral thrombosis. The patent claims are related to the following: LD heparin 10,5Kd (10-11 Kd) is used for the treatment and secondary prevention of ischemic stroke.
BACKGROUND: A pathogenic/likely pathogenic variant can be found in 20% to 25% of patients with Brugada syndrome (BrS) and a pathogenic/likely pathogenic variant in SCN5A is associated with a worse prognosis. The aim of this study is to define the diagnostic yield of a large gene panel with American College of Medical Genetics and Genomics variant classification and to assess prognosis of SCN5A and non-SCN5A variants.
METHODS: All patients with BrS, were prospectively enrolled in the Universitair Ziekenhuis Brussel registry between 1992 and 2022. Inclusion criteria for the study were (1) BrS diagnosis; (2) genetic analysis performed with a large gene panel; (3) classification of variants following American College of Medical Genetics and Genomics guidelines. Patients with a pathogenic/likely pathogenic variant in SCN5A were defined as SCN5A+. Patients with a reported variant in a non-SCN5A gene or with no reported variants were defined as patients with SCN5A-. All variants were classified as missense or predicted loss of function.
RESULTS: A total of 500 BrS patients were analyzed. A total of 104 patients (20.8%) were SCN5A+ and 396 patients (79.2%) were SCN5A-. A non-SCN5A gene variant was found in 75 patients (15.0%), of whom, 58 patients (77.3%) had a missense variant and 17 patients (22.7%) had a predicted loss of function variant. At a follow-up of 84.0 months, 48 patients (9.6%) experienced a ventricular arrhythmia (VA). Patients without any variant had higher VA-free survival, compared with carriers of a predicted loss of function variant in SCN5A+ or non-SCN5A genes. There was no difference in VA-free survival between patients without any variant and missense variant carriers in SCN5A+ or non-SCN5A genes. At Cox analysis, SCN5A+ or non-SCN5A predicted loss of function variant was an independent predictor of VA.
CONCLUSIONS: In a large BrS cohort, the yield for SCN5A+ is 20.8%. A predicted loss of function variant carrier is an independent predictor of VA.
Volleyball, invented by William Morgan in 1895, boasts a global participation of approximately 500 million people, making it a dynamic and fast-paced sport with diverse technical, tactical, and athletic demands. The game places high requirements on players' speed, agility, power, and strength. In the Netherlands, it is one of the most played team sports, with over 12,500 athletes participating. Volleyball is considered safer than other sports like football, handball, and basketball. Plyometric training (PT) is a key focus for coaches and professionals aiming to enhance players' conditioning capacities.

Plyometric jump training (PJT) has been identified as beneficial for both amateur and professional volleyball players, emphasizing the importance of training for repeated jumping, frequent sprinting, and directional changes. A meta-analysis by Ramirez et al. (2020) found that PJT effectively improved players in various age groups and genders while being deemed safe for volleyball players. Gjinovci et al. (2017) conducted a Randomized Control Trial, revealing greater improvements in plyometric group participants compared to skill-based training, particularly for sprinting, jumping, and throwing performance in players above 18 years of age.

Given the lack of a structured training plan for volleyball players, the study proposes implementing a structured plyometric training plan. This approach aims to enhance physical fitness and technical skills, including improved landing mechanics, increased explosive power, muscle strength, and agility. The study anticipates incorporating the structured plyometric training plan into the domestic players' training protocol, with a focus on improving rate of force development (RFD) for explosive movements such as jumping and spiking, as well as enhancing speed and agility for quick and coordinated on-court actions. The ultimate goal is to evaluate whether the proposed training plan positively impacts players' technical skills and physical fitness.
The present invention provides combination therapies for the treatment of a solid tumor cancer in a subject. In particular, the present invention provides methods for treating a solid tumor cancer in a subject comprising administering to said subject one or more immunomodulatory agents and tumor-targeted bacteria, preferably attenuated tumor-targeted bacteria. The present invention also provides methods for treating a solid tumor cancer in a subject comprising administering to said subject one or more immunomodulatory agents and tumor-targeted bacteria as vectors for the delivery of one or more therapeutic molecules. The methods of the invention improve the efficacy of tumor-targeted bacteria in the treatment of solid tumor cancers, while avoiding or limiting the adverse or unwanted side effects associated with the administration of bacteria to subjects whose immune system has been altered or compromised in some aspect by an immunomodulatory agent. The methods of the invention also provide more efficient local delivery of therapeutic molecules to the site of a solid tumor cancer using tumor-targeted bacteria engineered to express said therapeutic molecules. The present invention also provides compositions and kits comprising one or more immunomodulatory agents and one or more tumor-targeted bacteria, preferably attenuated tumor-targeted bacteria. The present invention further provides compositions and kits comprising one or more immunomodulatory agents and one or more tumor-targeted bacteria, wherein the tumor-targeted bacteria express one or more therapeutic molecules.
Proper and functional immune response requires a complex interaction between innate and adaptive immune cells, which dendritic cells (DCs) are the primary actors in this coordination as professional antigen-presenting cells. DCs are armed with numerous pattern recognition receptors (PRRs) such as nucleotide-binding and oligomerization domain-like receptors (NLRs) like NLRP3, which influence the development of their activation state upon sensation of ligands. NLRP3 is a crucial component of the immune system for protection against tumors and infectious agents, because its activation leads to the assembly of inflammasomes that cause the formation of active caspase-1 and stimulate the maturation and release of proinflammatory cytokines. But, when NLRP3 becomes overactivated, it plays a pathogenic role in the progression of several autoimmune disorders. So, NLRP3 activation is strictly regulated by diverse signaling pathways that are mentioned in detail in this review. Furthermore, the role of NLRP3 in all of the diverse immune cells' subsets is briefly mentioned in this study because NLRP3 plays a pivotal role in modulating other immune cells which are accompanied by DCs' responses and subsequently influence differentiation of T cells to diverse T helper subsets and even impact on cytotoxic CD8+ T cells' responses. This review sheds light on the functional and therapeutic role of NLRP3 in DCs and its contribution to the occurrence and progression of autoimmune disorders, prevention of diverse tumors' development, and recognition and annihilation of various infectious agents. Furthermore, we highlight NLRP3 targeting potential for improving DC-based immunotherapeutic approaches, to be used for the benefit of patients suffering from these disorders.
The invention discloses a drug for curing allergic rhinitis, and belongs to the medical preparation. The drug is prepared from following raw materials in parts by weight: 10 to 12 parts of radix paeoniae alba, 15 to 20 parts of radix astragali, 10 to 15 parts of phellodendron, 10 to 12 parts of ligusticum wallichii, 10 to 12 parts of xanthium, 10 to 15 parts of Chinese magnoliavine, 15 to 20 parts of dark plum, 10 to 12 parts of dahurian angelica root, 12 to 17 parts of wolfberry, 10 to 15 parts of epimeddium, 5 to 10 parts of dried ginger, 10 to 12 parts of chrysanthemum and 10 to 15 parts of poria cocos. The preparation method comprises following steps: washing and cleaning the raw materials, cooking the raw materials in a pottery cup or a brass cup or a copper pan, extracting the effective components, preparing the filtered medicine liquid into extract, drying, grinding, pulverizing into powder, and finally pressing into tablets or packaging in capsules. The drug for curing allergic rhinitis has been applied to the clinical use, and has a good curative effect on allergic rhinitis. The cure rate is over 80% and the effective rate is over 90%. The drug is suitable for allergic rhinitis patients.
Actively planning to conceive within approximately 12 months of study registration. No previous pregnancies.
Interoperable health IT allows for the reduction of barriers in the exchange of health information. Substantial work flow efficiencies and cost reductions may be realized by reducing these barriers, and integrating information exchange among different providers and healthcare systems. Some of the avenues in which these efficiencies and cost reductions are likely to be achieved are through easier access to test results, reduction in medication errors, quality monitoring and improvement methodologies, and increased consumer choice. In recognition of the potential for these improvements, New York State has provided funding to regional entities (Regional Health Information Organizations-RHIO'S) whose role is to assist practice providers in the development, implementation, and integration of these interoperable IT systems. New York State has also provided funding to evaluate the technology implementations facilitated by the RHIOs. The investigators will be working with health care providers that have been assisted by the Greater Rochester RHIO.

Depending on the unique characteristics of the hardware and software that is developed and implemented, there may be variations in operational flow that effect efficiency in the ambulatory care setting. The goal of our study is to measure and evaluate the effects of interoperable IT systems in the work flow practices of providers that have implemented them in the ambulatory care setting.
For the patients with locally advanced colon cancer, adjuvant FOLFOX and XELOX chemotherapy have become standard treatment. However, 30% - 40% patients suffered from local recurrence or distant metastasis after this standard treatment. Neoadjuvant chemotherapy could shrink tumors, eliminate micrometastasis, reduce surgical trauma and accelerate recovery. Hence, we evaluate the efficacy and safety of FOLFOXIRI as neoadjuvant chemotherapy in treating patients with locally advanced colon cancer.

In this prospective study, 30 patients with locally advanced colon cancer will be treated with 4 cycles of neoadjuvant FOLFOXIRI chemotherapy followed by surgical resection. PET-CT scanning will be performed before and after the neoadjuvant FOLFOXIRI chemotherapy to assess SUVmax changes. The ctDNA in peripheral blood before and after each cycle of neoadjuvant FOLFOXIRI chemotherapy will be detected. In the course of treatment, safety evaluation will be carried out according to adverse reaction classification (CTCAE) 4. 0.
we will conduct a single-arm phase I clinical study in 20 patients with acute myeloid leukemia (AML) at the stage of minimal residual disease (MRD) following standard chemotherapy, and these patients are not the subjects of stem cell transplantation. Adult patients between18 and 70 years old with AML who have entered morphological remission after induction, consolidation or intensive chemotherapy with molecular signature of increased WT1 molecule levels and pathological characteristics of bone marrow biopsy, together with fulfilling all other eligibility criteria, will be vaccinated with dendritic cells loaded with tri-antigens (WT1/TERT/survivin) in the absence of any additional therapeutic measurements. The primary aim of this innovative immunotherapy study is to determine whether the anti-leukemic effects seen in our preclinical study can be confirmed in patients and whether such DC vaccination can significantly prevent relapse and increase survival of AML patients by eradicating minimal residual disease. Patients will be recruited at 307 Hospital in Beijing. Recruitment will start in the second half of 2021 and will last for two years or until 20 safety and efficacy-evaluable AML patients are included. This is a single-arm trial. The patients who present MRD after complete chemotherapy will receive a conditioning regimen of cyclophosphamide, followed by six infusions of autologous or HLA-matched donor-derived DCs loaded with tri-antigens including WT1/TERT/survivin. The dendritic cell therapy product will be administered in the stem cell transplantation center at 307 Hospital headed by Dr. Liang-Ding Hu. After inclusion of 20 safety/feasibility-evaluable patients, relapse rate, relapse-free survival and overall survival analysis will be performed. Tumor marker levels and immune signature molecules will also be monitored at molecular and immunological levels, and general and disease-specific quality of life will be evaluated using quality of life questionnaires at various time points.
We plan to implement and evaluate a Home Telehealth Care Management System designed to enhance clinical care for congestive heart failure patients who have difficulty with access to care. Unique in this model is that in addition to use of protocol driven interventions (evidence based), the primary care physician is intimately involved in follwo up of patients- with consequent reduction in the fracture of care seen in with attendance in multiple specialty clinics.

In this project, we will evaluate the delivery of care to heart failure patients in Nova Scotia and New Brunswick, with our intervention and the current standard of care, which is the heart failure clinic. Home Telehealth technology will allow patients to be contacted and regularly evaluated in a comprehensive way in their own home, and without the need for a clinic visit. While the Project Team (experienced in heart failure management) will monitor all data, the Family Physician will have first hand access to and right of first treatment when alterations in therapy are needed. This process will be facilitated by the use of protocol driven medical therapy, and delegated medical functions, as well as set-piece education. We hope, with this technology and care plan, to offer the benefits of disease management to this vulnerable patient population while at the same time firmly placing the Family Physician in their central role within the health care system. This program will enable a specific assessment of all aspects of the program, including outcomes, quality of life, professional satisfaction and cost.
The exact mechanisms by which aspirin prevents the development of PE in high-risk patients are currently not fully known. Furthermore, a small proportion of high-risk patients who are on low-dose aspirin still go on to develop PE. This is a big unmet need because although it is known that this treatment is working for some patients, it is not known how it's working in these patients and also why a proportion of patients don't respond to this treatment. If the key mechanisms by which aspirin treatment is beneficial in patients at high risk of PE can be identifies, this will lead to better information for clinicians of why this treatment works and this could then be conveyed to the patient. Moreover, if key differences can be identified between aspirin responders and non-responders, novel therapeutic targets could be developed that could work for all patients at high risk of PE.

One of the main anti-inflammatory actions of aspirin is the release of aspirin-triggered lipoxin (ATL). The receptor for ATL (FPR2/ALX) is highly expressed on neutrophils, suggesting that the anti-inflammatory action of this drug is mediated via neutrophils. The investigators have previously shown that neutrophils are important in mediating anti-inflammatory responses in PE. Thus, taken together, the hypothesis is that neutrophils are key to understanding the mechanisms involved in the use of low-dose aspirin (LDA) treatment in patients at high risk of developing PE and key to understanding why this treatment does not work in some high-risk patients. This hypothesis will be addressed by two objectives both of which will entail in-depth profiling of neutrophils.
BACKGROUND: Chronic pain is a major health issue and rapid population ageing exacerbates the burden to health systems in countries like Germany. Nonpharmacological interventions (NPIs) are essential in pain care and the prioritization of active NPIs is emphasized in guidelines. This paper examines the utilization of NPIs for chronic pain management in community-dwelling older adults with a certified need of care in Berlin, Germany.
METHODS: Cross-sectional data was collected through standardized face-to-face surveys with older adults (≥65 years), using validated instruments (e.g., Brief Pain Inventory), and structured lists for NPI utilization. Categorization into active and passive NPIs was performed through a literature-based, iterative process by an interdisciplinary team. For not normally distributed data, non-parametric tests were used as appropriate. Logistic regression was conducted for multivariate analysis.
RESULTS: In total, 250 participants were included in this analysis (aged 65-104, x̅ = 81.8, 68.8% female). Most (92%) use NPIs for chronic pain management: 85.6% use active NPIs, 50.4% active movement and only 5.6% use solely passive approaches. Most common NPIs are distraction, thermotherapy/compresses, and physiotherapy. The odds of utilizing physiotherapy are three times higher for those with high educational status when compared to those with low education while those with low educational status had higher odds of using thermotherapy/compresses.
CONCLUSIONS: In our sample, most community-dwelling older adults with a certified need of care use active NPIs for chronic pain management with about half using active movement approaches. Considering the high vulnerability of this population, physiotherapy (in the form of therapeutic exercise) is a particularly appropriate intervention, and it was the third most frequent NPI in our sample. However, there is a social gradient in the utilization of physiotherapy for chronic pain management which might be rooted in issues around awareness, appeal, and access to such measures. It is important to take socioeconomic differences into account when planning the care for older chronic pain patients but also when designing research or user-friendly guidelines for this target group.
TRIAL REGISTRATION: Ethical approval from the Ethics Committee of Charité - Universitätsmedizin Berlin (EA1/368/14) and study registration with the Central Study Register (ZSR no. 20009093).
Individuals self-selecting the control arm receive the current standard of care for prediabetes, which is a one-time 2-hour group education session. In addition, the individuals are asked to provide some information at baseline and 6 months and 1 year later. The information collected will include a record of dietary and physical activity habits and whether or not they have developed Type 2 diabetes.
Provided is a magnet body which can be suitably applied to a drug delivery system which utilizes magnetism. Also provided is a drug delivery control device which is configured so that a magnet body can be suitably applied to drug delivery. A magnet body is provided with a magnet and a cover body which is attached to an end of the magnet. The cover body consists of a material having a high magnetic permeability, and the ratio between the length and the diameter of the cover body is in the range from 10:1 to 7:3. A drug delivery control device is provided with: a magnet body having a magnet and a cover body which is attached to an end of the magnet; a head for supporting the magnet body; and a head drive mechanism for operating the head along a projected region which is formed on a tissue surface by an affected part. The magnet body applies a magnetic field to the affected part to which a magnetic medication has been delivered.
Sarcopenia is characterized by loss of muscle strength and muscle mass with aging. The growing number of sarcopenia patients as a result of the aging population has no viable treatment. Exercise maintains muscle strength and mass by increasing peroxisome growth factor activating receptor γ-conjugating factor-1α (PGC-1α) and Akt signaling in skeletal muscle. The present study focused on the carbon monoxide (CO), endogenous activator of PGC-1α and Akt, and investigated the therapeutic potential of CO-loaded red blood cells (CO-RBCs), which is bioinspired from in vivo CO delivery system, as an exercise mimetic for the treatment of sarcopenia. Treatment of C2C12 myoblasts with the CO-donor increased the protein levels of PGC-1α which enhanced mitochondrial biogenesis and energy production. The CO-donor treatment also activated Akt, indicating that CO promotes muscle synthesis. CO levels were significantly elevated in the skeletal muscle of normal mice after intravenous administration of CO-RBCs. Furthermore, CO-RBCs restored the mRNA expression levels of PGC-1α in the skeletal muscle of two experimental sarcopenia mouse models, denervated (Den) and hindlimb unloading (HU) models. CO-RBCs also restored muscle mass in Den mice by activating Akt signaling and suppressing the muscle atrophy factors myostatin and atrogin-1, and oxidative stress. Treadmill tests further showed that the reduced running distance in HU mice was significantly restored by CO-RBC administration. These findings suggest that CO-RBCs have potential as an exercise mimetic for sarcopenia treatment.